ArticleClinical and translational radiation oncology2026
Prospective evaluation of acute side effects profiles in moderately hypofractionated whole-pelvic radiotherapy for prostate cancer.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Outcomes of whole-pelvic radiotherapy (WPRT) in the era of moderately hypofractionated radiotherapy for prostate cancer remain sparsely reported. Previous studies indicate a high discrepancy between patient-reported outcomes (PROs) and clinician-reported outcomes (CROs) assessing the same endpoint. This study analyzed the concordance between PROs and CROs for WPRT and prostate-only radiotherapy (PRT) patients. Methods: Patients received a prescribed dose of 20 × 3 Gy to the planning target volume (PTV) and, in cases of lymph node involvement, 46 Gy to the regional lymph nodes. 176 WPRT and 62 PRT patients reported genitourinary (GU) and gastrointestinal (GI) adverse events through an electronic patient-reported outcome measures tool. Simultaneously, clinicians graded side effects using Radiation Therapy Oncology Group (RTOG) criteria for up to two years post-radiotherapy. Composite GU and GI PRO scores, derived by averaging endpoints, were evaluated for their ability to discriminate RTOG Results: During treatment, WPRT patients exhibited elevated GI scores compared to PRT patients via PROs (mean: 2.80 vs. 2.48, p=0.010) and CROs (mean: 1.15 vs. 0.89, p=0.014), though levels equalized by 12 months. Composite PRO scores demonstrated moderate-to-good discriminatory performance for elevated CRO levels (areas under the curves: GI 0.65-0.74; GU 0.73-0.82) from the acute phase through 24 months. Conclusion: WPRT was associated with increased acute GI adverse effects but showed recovery to PRT levels within one year. Results demonstrated that PROs yield clinically relevant discriminatory value. Routine integration of PROs may facilitates earlier adverse event identification, allocation of clinical resources, and individualized clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.